We’ve updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How has the artery stenosis drug grown historically, and what trends indicate future expansion?
The artery stenosis drug market size has grown strongly in recent years. It will grow from $2.47 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising incidence of cardiovascular diseases, growing geriatric population, increasing awareness about arterial health, growing use of telemedicine in patient monitoring, and improved healthcare infrastructure.
The artery stenosis drug market size is expected to see strong growth in the next few years. It will grow to $3.34 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing obesity and diabetes prevalence, growing demand for minimally invasive treatments, expansion of healthcare access in emerging markets, rising healthcare expenditure, and rising prevalence of diabetes and obesity. Major trends in the forecast period include personalized medicine approaches, increased adoption of combination therapies, advancements in diagnostic techniques, rising focus on preventative cardiology, and development of novel drug delivery systems.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24151&type=smp
Which key factors are driving the expansion of the artery stenosis drug industry?
The rising prevalence of diabetes and obesity is expected to propel the growth of the artery stenosis drug market going forward. Diabetes is a long-term condition where the body either produces insufficient insulin or is unable to use it properly, resulting in elevated blood sugar levels, whereas obesity is a health condition marked by an excess of body fat, raising the likelihood of numerous health issues. This rise in diabetes and obesity is growing due to a lack of regular physical activity associated with increasingly sedentary work environments and screen-based leisure activities, which contribute to weight gain and insulin resistance. Artery stenosis drugs are needed in diabetes and obesity, as both conditions promote plaque buildup in arteries, increasing the risk of heart attacks and strokes. For instance, in March 2024, according to the World Health Organization, a Switzerland-based agency of the United Nations, in 2022, 2.5 billion adults were overweight, with 890 million living with obesity. Therefore, the growing prevalence of diabetes and obesity is driving growth in the artery stenosis drug market.
How is the artery stenosis drug market segmented by product, application, and end-user?
The artery stenosis drug market covered in this report is segmented –
1) By Drug Type: Antiplatelet Agents, Anticoagulants, Statins, Beta Blockers
2) By Mechanism Of Action: Platelet Aggregation Inhibitors, Thrombin Inhibitors, HMG-CoA Reductase Inhibitors, Beta-Adrenergic Antagonists
3) By Route Of Administration: Oral, Injectable, Transdermal
4) By Patient Type: Adults, Geriatric, Pediatric
Subsegments:
1) By Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dipyridamole
2) By Anticoagulants: Warfarin, Heparin, Low Molecular Weight Heparins, Direct Oral Anticoagulants (DOACs)
3) By Statins: Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin, Lovastatin
4) By Beta Blockers: Metoprolol, Atenolol, Propranolol, Carvedilol, Bisoprolol
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/artery-stenosis-drug-global-market-report
Which major trends are influencing the growth of the artery stenosis drug industry?
Major companies operating in the artery stenosis drug market are focusing on advancing therapeutic solutions, such as bempedoic acid, to address unmet medical needs in the treatment of hypercholesterolemia. Bempedoic acid is a first-in-class drug designed to lower LDL cholesterol levels in patients who cannot tolerate statins or need additional lipid-lowering therapy. For instance, in May 2022, Zydus Lifesciences Ltd., an India-based pharmaceutical company, launched Bemdac, a novel oral therapy for hypercholesterolemia, a new class of drug, in India. Bemdac contains bempedoic acid, a first-in-class drug designed to lower LDL cholesterol levels in patients who are unable to tolerate statins or require additional lipid-lowering therapy. The launch aims to provide a new treatment option that improves cardiovascular outcomes by targeting cholesterol synthesis in the liver while minimizing muscle-related side effects often associated with statin use.
Which leading companies are dominating the artery stenosis drug market landscape?
Major companies operating in the artery stenosis drug market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals.
Which geographic areas are expected to offer the highest growth opportunities in theartery stenosis drug market?
North America was the largest region in the artery stenosis drug market in 2024. The regions covered in the artery stenosis drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Artery Stenosis Drug Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24151&type=smp
Need Customized Data On Artery Stenosis Drug Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24151&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
